دورية أكاديمية
أعرض في EDS

Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond

التفاصيل البيبلوغرافية
العنوان: Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
المؤلفون: Christopher T. Su, J. Christine Ye
المصدر: Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-18 (2021)
بيانات النشر: BMC, 2021.
سنة النشر: 2021
المجموعة: LCC:Diseases of the blood and blood-forming organs
LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
مصطلحات موضوعية: Multiple myeloma, Review, First in human trials, Chimeric antigen receptor, CAR-T, Bispecific antibody, Diseases of the blood and blood-forming organs, RC633-647.5, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
الوصف: Abstract The pace of innovation of multiple myeloma therapy in recent years is remarkable with the advent of monoclonal antibodies and the approval of novel agents with new mechanisms of action. Emerging therapies are on the horizon for clinical approval with significant implications in extending patient survival and advancing closer to the goal of a cure, especially in areas of immunotherapy such as chimeric antigen receptor T cells, bispecific T cell engager antibodies, antibody drug conjugates, newer generations of monoclonal antibodies, and small molecule inhibitor and modulators. This review provides an update of current myeloma therapeutics in active preclinical and early clinical development and discusses the mechanism of action of several classes of novel therapeutics.
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 1756-8722
Relation: https://doaj.org/toc/1756-8722
DOI: 10.1186/s13045-021-01109-y
URL الوصول: https://doaj.org/article/6cf63a061d784f869babf80b36a25ea1
رقم الأكسشن: edsdoj.6cf63a061d784f869babf80b36a25ea1
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:17568722
DOI:10.1186/s13045-021-01109-y